{"nctId":"NCT02635984","briefTitle":"Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens","startDateStruct":{"date":"2015-11","type":"ACTUAL"},"conditions":["Complications of Bone Marrow Transplant","Hematologic Neoplasms"],"count":108,"armGroups":[{"label":"Triplet Therapy Plus Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Triplet Therapy Plus Olanzapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]}],"interventions":[{"name":"Olanzapine","otherNames":["Zyprexa"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inpatient or outpatient hematology patient receiving one of the following regimens:\n* Chemotherapy for hematologic malignancy:\n* ABVD\n* ICE ± R\n* 7+3\n* Conditioning therapy for stem cell transplantation:\n* BEAM\n* Bu/Cy ± ATG\n* Bu/Flu ± ATG\n* FluCy ± ATG\n* FluCy + TBI\n* BuMel\n* FluBuCy\n* Melphalan\n* Etoposide + TBI\n* Cyclophosphamide + TBI\n\nExclusion Criteria:\n\n* Allergy to olanzapine\n* Documented nausea or vomiting ≤24 hours prior to enrollment\n* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to enrollment or planned during protocol therapy\n* Chronic alcoholism\n* Pregnant\n* Declined or unable to provide an informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Percentage of Patients Who Had a Complete Response","description":"Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (\\< 25 mm on a 100 mm visual analog scale \\[VAS\\]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With no Significant Nausea in Overall Assessment Period","description":"Reported for overall phases \\[chemotherapy days plus 5 days after\\] where all VAS \\< 25 mm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Achieving Complete Protection in Overall Assessment Phase","description":"(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases \\[chemotherapy days plus 5 days after\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With no Significant Nausea in Acute Phase","description":"Reported as acute \\[chemotherapy days\\]. All assessment with all VAS \\< 25 mm on days of chemotherapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With no Significant Nausea in Delayed Phase","description":"Reported for delayed \\[5 days after chemotherapy administration\\] All assessment with all VAS \\< 25 mm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With no Nausea in Overall Assessment Period","description":"No nausea (all VAS \\<5 mm) in overall assessment period (days of chemotherapy plus five days after)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With Complete Response in Acute Phase","description":"Complete response (no emesis and no more than minimal nausea, defined as \\< 25 mm on a 100 mm visual analog scale \\[VAS\\]) in acute phase (days of chemotherapy)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With Complete Response in Delayed Phase","description":"Complete response (no emesis and no more than minimal nausea, defined as \\< 25 mm on a 100 mm visual analog scale \\[VAS\\]) in delayed phase (5 days after chemotherapy)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Withdrawal From Study"]}}}